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SUPPLEMENTAL TABLE 1. Treatment Results by Treatment Group Stratified by BMI. 
BMI < 30 (N=179) BMI 30-34 (N=135) BMI ≥ 35 (N=311) 
 
 
 
 
  
Clomiphene 
Citrate (n=57) 
Metformin 
XR (n=57) 
Combined 
Clomiphene and 
Metformin (n=65) 
Clomiphene 
Citrate (n=42) 
Metformin 
XR (n=45) 
Combined 
Clomiphene 
And 
Metformin 
(n=48) 
Clomiphene 
Citrate (n=110) 
Metformin 
XR (n=105) 
Combined 
Clomiphene 
And Metformin 
(n=96) 
Mean (SD) BMI 25.2 (3.2) 25.3 (3.2) 24.6 (3.3) 32.6 (1.4) 32.4 (1.3) 32.5 (1.6) 42.8 (6.0) 42.6 (5.2) 41.5 (5.3) 
Ovulation 135/222 
(60.8%) 
100/261 
(38.3%) 
219/300 (73.0%) 103/173 
(59.5%) 
99/225 
(44.0%) 
134/222 
(60.4%) 
224/547 
(41.0%) 
97/530 
(18.3%) 
229/442 
(51.8%) 
Conception 24/57 (42.1%) 12/57 (21.1%) 30/65 (46.2%) 12/42 (28.6%) 8/45 (17.8%) 16/48 (33.3%) 26/110 (23.6%) 5/105 (4.8%) 34/96 (35.4%) 
Pregnancy 21/57 (36.8%) 7/57 (12.3%) 26/65 (40.0%) 8/42 (19.0%) 7/45 (15.6%) 10/48 (20.8%) 21/110 (19.1%) 4/105 (3.8%) 29/96 (30.2%) 
Singleton 19/21 (90.5%) 7/7 (100.0%) 25/26 (96.2%) 8/8 (100.0%) 7/7 (100.0%) 9/10 (90.0%) 20/21 (95.2%) 4/4 (100.0%) 29/29 (100.0%) 
Twins 1/21 (4.8%) 0 1/26 (3.8%) 0 0 1/10 (10.0%) 1/21 (4.8%) 0 0 
Triplets 1/21 (4.8%) 0 0 0 0 0 0 0 0 
Other 0 0 0 0 0 0 0 0 0 
Live Birth 21/57 (36.8%) 5/57 (8.8%) 24/65 (36.9%) 8/42 (19.0%) 6/45 (13.3%) 10/48 (20.8%) 18/110 (16.4%) 4/105 (3.8%) 22/96 (22.9%) 
All pregnancy loss 
among patients who 
conceived 
4/24 (16.7%) 7/12 (58.3%) 6/30 (20.0%) 4/12 (33.3%) 2/8 (25.0%) 6/16 (37.5%) 8/26 (30.1%) 1/5 (20.0%) 12/34 (35.3%) 
1st trimester loss 3/24 (12.5%) 7/12 (58.3%) 4/30 (13.3%) 4/12 (33.3%) 2/8 (25.0%) 6/16 (37.5%) 7/26 (26.9%) 1/5 (20.0%) 10/34 (29.4%) 
Biochemical or 
no fetal heart 
beat 
1/24 (4.2%) 5/12 (41.7%) 4/30 (13.3%) 4/12 (33.3%) 1/8 (12.5%) 5/16 (31.3%) 5/26 (19.2%) 1/5 (20.0%) 4/34 (11.8%) 
Ectopic 2/24 (8.3%) 0/12 (0.0%) 0/30 (0.0%) 0/12 (0.0%) 0/8 (0.0%) 1/16 (6.3%) 0/26 (0.0%) 0/5 (0.0%) 1/34 (2.9%) 
Loss after 
observed heart 
beat 
0/24 (0.0%) 2/12 (16.7%) 0/30 (0.0%) 0/12 (0.0%) 1/8 (12.5%) 0/16 (0.0%) 2/26 (7.7%) 0/5 (0.0%) 5/34 (14.7) 
2nd-3rd trimester 
loss 
1/24 (4.2%) 0/12 (0.0%) 2/30 (6.7%) 0/12 (0.0%) 0/8 (0.0%) 0/16 (0.0%) 1/26 (3.8%) 0/5 (0.0%) 2/34 (5.9%) 
Ovulation was defined by a serum progesterone level > 5 ng/mL; Conception was defined as any positive serum hCG level; Pregnancy 
defined as an intrauterine pregnancy with fetal heart motion as determined by transvaginal ultrasound; and Live Birth defined as delivery of 
any viable infant. 
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SUPPLEMENTAL TABLE 2. Results by Treatment Group Stratified by Previous Therapy. 
 Previous Therapy (N=343) No Previous Therapy (N=283) 
  Clomiphene Citrate 
(n=116) 
Metformin XR 
(n=111) 
Combined 
Clomiphene and 
Metformin (n=116) 
Clomiphene Citrate 
(n=93) 
Metformin XR (n=97) Combined 
Clomiphene and 
Metformin (n=93) 
Ovulation 272/538 (50.6%) 151/554 (27.3%) 334/559 (59.7%) 190/404 (47.0%) 145/465 (31.2%) 248/405 (61.2%) 
Conception 32/116 (27.6%) 13/111 (11.7%) 39/116 (33.6%) 30/93 (32.3%) 12/97 (12.4%) 41/93 (44.1%) 
Pregnancy 24/116 (20.7%) 8/111 (7.2%) 31/116 (26.7%) 26/93 (28.0%) 10/97 (10.3%) 34/93 (36.6%) 
Singleton 24/24 (100.0%) 8/8 (100.0%) 30/31 (96.8%) 23/26 (88.5%) 10/10 (100.0%) 33/34 (97.1%) 
Twins    0    0 1/31 (3.2%) 2/26 (7.7%)    0 1/34 (2.9%) 
Triplets    0    0    0 1/26 (3.8%)    0    0 
Other    0    0    0    0    0    0 
Live Births 23/116 (19.8%) 6/111 (5.4%) 26/116 (22.4%) 24/93 (25.8%) 9/97 (9.3%) 30/93 (32.3%) 
All pregnancy loss among patients 
who conceived 
9/32 (28.1%) 7/13 (53.9%) 13/39 (33.3%) 7/30 (23.3%) 3/12 (25.0%) 11/41 (26.8%) 
1st trimester loss 9/32 (28.1%)  7/13 (53.9%) 11/39 (28.2%)  5/30 (16.7%) 3/12 (25.0%) 9/41 (22.0%) 
Biochemical or no fetal heart beat 6/31 (18.8%) 5/13 (38.5%) 8/39 (20.5%) 4/30 (13.3%) 2/12 (16.7%) 5/41 (12.2%) 
Ectopic 2/31 (6.3%) 0/13 (0.0%) 0/39 (0.0%) 0/30 (0.0%) 0/12 (0.0%) 2/41 (4.9%) 
Loss after observed heart beat 1/31 (3.1%) 2/13 (15.4%) 3/39 (7.7%) 1/30 (3.3%) 1/12 (8.3%) 2/41 (4.9%) 
2nd-3rd trimester loss 0/32 (0.0%) 0/13 (0.0%) 2/39 (5.1%) 2/30 (6.7%) 0/12 (0.0%) 2/41 (4.9%) 
Ovulation was defined by a serum progesterone level > 5 ng/mL; Conception was defined as any positive serum hCG level; Pregnancy 
defined as an intrauterine pregnancy with fetal heart motion as determined by transvaginal ultrasound; and Live Birth defined as delivery of 
any viable infant. 
